Tania Crough

TL;DR: Over the last decade, knowledge of the immune response to HCMV infection in healthy virus carriers and diseased individuals has allowed us to translate these findings to develop better diagnostic tools and therapeutic strategies, and the application of these emerging technologies in the clinical setting is likely to provide opportunities for better management of patients with H CMV-associated diseases.

TL;DR: It is found that successful HCMV-specific immune control in healthy virus carriers is dependent on a strong T-cell response towards a broad repertoire of antigens, which contrasts with previous findings that viral interference with the antigen-processing pathway during lytic infection would render immediate-early and early/late proteins less immunogenic.

TL;DR: Evaluation of QuantiFERON®‐CMV in healthy individuals revealed that this technology was at least as sensitive and with some HCMV epitopes more sensitive than the ELISPOT for detecting ex vivo IFN‐γ, and may be a valuable diagnostic test for the detection of H CMV infection and a useful clinical tool for monitoring the immune response in immunosuppressed patients during therapy.

TL;DR: It is suggested that a combination therapy with autologous CMV-specific T cells and chemotherapy is a safe novel treatment option and may offer clinical benefit for patients with recurrent GBM.

TL;DR: QuantiFERON-CMV® testing in the week following CMV viremia can be useful in identifying HSCT recipients at risk of complicated reactivation and a failure to reconstitute CMV-specific immunity soon after the onset of CMV viraemia was associated with higher peak viral loads.